Curative Inc., created in January 2020 with the intent of improving diagnostics for sepsis, pivoted to SARS-CoV-2 testing in March 2020 as it became clear that the United States needed additional testing capacity. Cell Systems spoke with Curative cofounders Fred Turner, Dr. Isaac Turner, and Dr. Vlad Slepnev about their work developing and deploying a COVID-19 oral fluid test at scale with unprecedented speed.

中文翻译：

---

重新定义医疗保健的同时进行大规模COVID-19测试：专访联合创始人弗雷德·特纳，艾萨克·特纳和弗拉德·斯列普涅夫

Curative Inc.创建于2020年1月，旨在改善败血症的诊断能力，由于很明显美国需要额外的测试能力，因此于2020年3月转向SARS-CoV-2测试。Cell Systems与Curative联合创始人Fred Turner，Isaac Turner博士和Vlad Slepnev博士进行了交谈，讨论了他们以前所未有的速度开发和部署COVID-19口服液测试的工作。